Oncology

With pivotal lung cancer data imminent, ArriVent BioPharma juggles a high-risk, high-reward strategy, betting its future on a novel drug and a new wave of ‘smart bomb’ therapies.

RyboDyn's RyboCypher platform is uncovering a 'dark proteome' full of tumor-specific targets, promising a new era beyond today's crowded drug pipeline.

Amid a selective biotech market, Rakovina Therapeutics' oversubscribed placement highlights investor belief in its AI-powered strategy for next-gen cancer drugs.

BridgeBio Oncology is doubling down on a costly strategy, betting that combining its novel drugs is the key to defeating hard-to-treat RAS-driven cancers.

With pivotal data imminent for two cancer drugs and a fortified balance sheet, SELLAS is at a crucial inflection point. Can it deliver on its promise?

Quebec's funding for Roche's Itovebi offers new hope for breast cancer patients, but its complex approval reveals a national struggle over drug costs and access.

Stand Up To Cancer funds a bold new strategy against pancreatic cancer, pairing an mRNA vaccine with cellular therapy to finally target the elusive KRAS gene.

With promising data for its lead cancer drug and a fortified financial runway, C4 Therapeutics is executing a tangible plan to fight a relentless disease.

With 92% response rates in a deadly cancer and $1B in the bank, Tango Therapeutics is not just developing a drug—it's building a new industrial model for precision oncology.

As Johnson & Johnson prepares for a key investor conference, its strategy hinges on a potent mix of new drugs, robotic surgery, and a leaner focus.

ITM’s promising cancer drug ITM-11 hits a delay, not for its science, but for manufacturing. A classic 'prototype to profit' hurdle with big implications.

The University of New Mexico Comprehensive Cancer Center joins the Caris Precision Oncology Alliance, bringing advanced AI-driven diagnostics to the Southwest.

Starling Oncology just hit positive Adjusted EBITDA, a milestone for its value-based care model. Is this the inflection point for profitability in oncology?

Zentalis Pharmaceuticals is pursuing a dual strategy for its ovarian cancer drug, azenosertib, aiming for fast market entry while securing long-term validation.

A new Health Canada approval for Regeneron's Libtayo offers a breakthrough for high-risk skin cancer patients and a strategic win for the company.

With spending up and losses widening, CG Oncology is leveraging its $1B cash reserve to push its promising bladder cancer drug toward a Q4 FDA submission.

Delcath Systems posts strong revenue and profits, but the real story is its massive investment in expanding its unique liver therapy to fight breast cancer and more.

A new clinical trial is testing a novel oncolytic virus, VCN-01, to break down pancreatic cancer's defenses, a key step toward a pivotal therapy.

Beyond the clinical data, ALX Oncology's latest update reveals a masterclass in strategic finance and leadership, positioning it for critical milestones.

Evolent Health touts soaring revenues and a major oncology deal, yet falling profits and rising medical costs reveal a challenging road ahead. Can AI deliver the efficiency it needs?